By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Immunization are discussed in a new report. According to news reporting out of Austin, Texas, by NewsRx editors, research stated, "Ebola is a highly virulent pathogen causing severe hemorrhagic fever with a high case fatality rate in humans and non-human primates (NHPs). Although safe and effective vaccines or other medicinal agents to block Ebola infection are currently unavailable, a significant effort has been put forth to identify several promising candidates for the treatment and prevention of Ebola hemorrhagic fever."
Our news journalists obtained a quote from the research from the University of Texas, "Among these, recombinant adenovirus-based vectors have been identified as potent vaccine candidates, with some affording both pre- and post-exposure protection from the virus. Recently, Investigational New Drug (IND) applications have been approved by the US Food and Drug Administration (FDA) and phase I clinical trials have been initiated for two small-molecule therapeutics: anti-sense phosphorodiamidate morpholino oligomers (PMOs: AVI-6002, AVI-6003) and lipid nanoparticle/small interfering RNA (LNP/siRNA: TKM-Ebola). These potential alternatives to vector-based vaccines require multiple doses to achieve therapeutic efficacy, which is not ideal with regard to patient compliance and outbreak scenarios. These concerns have fueled a quest for even better vaccination and treatment strategies. Here, we summarize recent advances in vaccines or post-exposure therapeutics for prevention of Ebola hemorrhagic fever."
According to the news editors, the research concluded: "The utility of novel pharmaceutical approaches to refine and overcome barriers associated with the most promising therapeutic platforms are also discussed."
For more information on this research see: Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment. Biodrugs, 2013;27(6):565-583. Biodrugs can be contacted at: Adis Int Ltd, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand (see also Immunization).
Our news journalists report that additional information may be obtained by contacting J.H. Choi, Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712, United States.
Keywords for this news article include: Texas, Viral, Austin, Viruses, Vaccines, Virology, Treatment, Ebola Virus, Immunization, Therapeutics, United States, Biological Products, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC